Shanghai Fosun Pharmaceutical's (Group) (HKG:2196, SHA:600196) subsidiary Fosun Adgenvax (Chengdu) Biopharmaceutical obtained the National Medical Products Administration's approval for clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine, a Tuesday bourse filing said.
Fosun Adgenvax (Chengdu) Biopharmaceutical plans to start the first phase of clinical trials in China.
The vaccine is a preventive biological product used for the prevention of certain infectious diseases caused by certain pneumococcal serotypes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.